The shares of Dr Reddy's Laboratories tumbled another 4% on Friday, extending their decline to more than 9% over two days after the company said commercial supplies of its semaglutide product would be delayed due to a quality-related issue involving the active pharmaceutical ingredient (API) used in certain batches.
The pharma company's shares fell to Rs 1,222 apiece, their lowest level in nearly three months, wiping out more than Rs 10,600 crore in market capitalisation over two sessions and taking its market value below Rs 1.02 lakh crore.
